PHGE: BiomX Forward P/S Multiple

Public company logo of BiomX Inc (PHGE)

The projected P/S metric exhibits volatility as BiomX Inc. prepares its methods for combating resistant bacteria for sale. The 7.10 mark characterizes this parameter, with a closed-loop therapy based on phage cocktails serving as the foundation. However, the clinical testing stage is increasing laboratory expenses, which temporarily neutralizes the company's operating leverage.

PHGE BiomX Inc: Market Cap to Future Revenue Ratio in the range 08/21/2026 - 09/11/2026

Analytical breakdowns for BiomX Inc.

- stock price and consensus target price:
Stock Quotes BiomX|PHGE - Analyst Forecast Prices
- market capitalization information:
Market Capitalization PHGE|PHGE - Company Buyout Price
- issuer book value statistics:
Net Assets per Single Share BiomX|PHGE - Total Stockholders' Equity|Market Value to Book Value Ratio biomx.com|PHGE - Total Business Assets
- company liabilities and liquidity data:
Debt to Equity BiomX Inc.|PHGE - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Capital BiomX|PHGE - Company Debts|Debts to Book Capitalization PHGE|PHGE - Long-Term Debt Volume|Company Short-Term Debt BiomX|Quick Liquidity biomx.com
- business earnings and investment ratios data:
PHGE - Net Income|Future Profit BiomX Inc.|PHGE - Price to Earnings Multiple|Projected Price to Earnings BiomX|PHGE - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple PHGE|PHGE - Operating income before deduction of amortization|Earnings per share for the last twelve months BiomX|PHGE - Earnings per share for the last 12 months|Quarterly EPS earnings growth biomx.com|PHGE - Net earnings per share growth this year|Expected earnings per share growth for next year BiomX Inc.
- revenue and sales details:
PHGE - Company Gross Revenue|Company Projected Revenue BiomX|PHGE - Price-to-Sales Ratio|Forward P/S Multiple PHGE
Summary company analytics:BiomX Ltd PHGE
Original product of biomx.com

For BiomX Inc. (PHGE), which is restructuring its R&D portfolio to accelerate clinical trials, this indicator serves as a tool to verify market value relative to expected cash flows. By analyzing the forward price-to-sales ratio, an investor correlates current market capitalization with expected annual revenue, making it possible to distinguish fundamental asset undervaluation from systemic risks during the management's operational adaptation period.

Analysis of competing companies

Summit Therapeutics Inc. - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio MRNA (Moderna Inc)|Vaxcyte Corp - Forward P/S Multiple|Market Cap to Expected Sales Ratio Tarsus Corp TARS|CorMedix Inc. (CRMD) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio serestherapeutics.com (MCRB)|Price-to-Projected Revenue Ratio Spero Therapeutics, Inc.|Market Cap to Projected Revenue SCYX (Scynexis)|Price-to-Projected Revenue Ratio AN2 Therapeutics, Inc. (ANTX)|Market Cap to Expected Sales Ratio polypid.com|Forward P/S Multiple LSB (LakeShore Biopharma Co.)|Iterum Therapeutics PLC - Price-to-Projected Revenue Ratio|BioPharma Bio - Forward P/S Multiple|Market Cap to Expected Sales Ratio 60 Degrees Pharmaceuticals SXTP|Oragenics (OGEN) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio OpGen Corporation (OPGN)